Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
5 Top-Ranked Stocks Empowered by DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
by Zacks Equity Research
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
Bet on These 5 Stocks With Exciting Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Amedisys (AMED) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR
Top Ranked Momentum Stocks to Buy for June 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 21st.
Bet Big on DuPont Analysis With These Top 5 Picks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than a simple ROE calculation? Bet on these five stocks then.
Here is Why Growth Investors Should Buy Amedisys (AMED) Now
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos
by Zacks Equity Research
Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos
5 Stocks With Impressive Interest Coverage Ratio to Buy Now
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR
by Zacks Equity Research
Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amedisys (AMED) Down 9.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Trade War Scaring You? Buy 5 DuPont-Tested Quality Stocks
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.
Here is Why Growth Investors Should Buy Amedisys (AMED) Now
by Zacks Equity Research
Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
by Zacks Equity Research
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
5 Stocks With Upgraded Broker Ratings Worth Betting on Now
by Swayta Shah
Brokers have more understanding of fundamentals of a company, and also about the overall economy. So, following broker advice is a wise decision.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1
by Zacks Equity Research
At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Raytheon, Otter, Amedysis, Tutor and DMC
by Zacks Equity Research
Zacks.com featured highlights include: Raytheon, Otter, Amedysis, Tutor and DMC
Amedisys (AMED) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Buy These 5 Low Leverage Stocks to Avoid Huge Losses
by Zacks Equity Research
Companies with large debt loads are more vulnerable during economic downturns and can even go bankrupt in the worst-case scenario
These 5 Stocks Boast Impressive Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Amedisys (AMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
by Zacks Equity Research
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.